Radiotherapy is undervalued in Germany, claims expert
This article was originally published in Clinica
Innovative radiation technology is not adequately reimbursed in Germany," says the German society for radio-oncology (DEGRO). Speaking in Berlin last week, DEGRO president Wolfgang Hinkelbein warned that by 2004, cancer would replace circulatory diseases as the most common cause of death in Germany. Investment in radiotherapy, however, was severely lacking, he said.
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.